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Abstract 
Background: Rapid diagnostic tests (RDTs) that detect histidine-rich protein 2 (PfHRP2) are used throughout Africa 
for the diagnosis of Plasmodium falciparum malaria. However, recent reports indicate that parasites lacking the pfhrp2 
and/or histidine-rich protein 3 (pfhrp3) genes, which produce antigens detected by these RDTs, are common in select 
regions of South America, Asia, and Africa. Proving the absence of a gene is challenging, and multiple PCR assays tar-
geting these genes have been described. A detailed characterization and comparison of published assays is needed 
to facilitate robust and streamlined testing approaches.
Results: Among six pfhrp2 and pfhrp3 PCR assays tested, the lower limit of detection ranged from 0.01 pg/µL to 
0.1 ng/µL of P. falciparum 3D7 strain DNA, or approximately 0.4–4000 parasite genomes/µL. By lowering the elonga-
tion temperature to 60 °C, a tenfold improvement in the limit of detection and/or darker bands for all exon 1 targets 
and for the first-round reaction of a single exon 2 target was achieved. Additionally, assays targeting exon 1 of either 
gene yielded spurious amplification of the paralogous gene. Using these data, an optimized testing algorithm for the 
detection of pfhrp2- and pfhrp3-negative P. falciparum is proposed.
Conclusions: Surveillance of pfhrp2- and pfhrp3-negative P. falciparum requires careful laboratory workflows. PCR-
based testing methods coupled with microscopy and/or antigen testing serve as useful tools to support policy devel-
opment. Standardized approaches to the detection of pfhrp2- and pfhrp3-negative P. falciparum should inform efforts 
to define the impact of these parasites.
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Background
Diagnostic testing is a core component of recent malaria 
control efforts. In Africa, where the majority of deaths 
due to malaria occur, rapid diagnostic tests (RDTs) are 
the most commonly employed malaria diagnostic strat-
egy, accounting for 74% of diagnostic testing among sus-
pected malaria cases [1]. The most commonly used RDTs 
in Africa rely upon detection of PfHRP2, a Plasmodium 
falciparum-specific antigen expressed by the histidine-
rich protein 2 (pfhrp2) gene. However, recent reports 
from select locations in South America, Asia, and Africa 
of P. falciparum parasites lacking pfhrp2 and/or the his-
tidine-rich protein 3 (pfhrp3) gene, which produces an 
antigen that cross reacts with some PfHRP2-based RDTs, 
raise concerns about the effectiveness of PfHRP2-based 
RDTs in affected regions [2–18]. In response, the World 
Health Organization (WHO) has prioritized efforts to 
address parasites with deletions of the pfhrp2 and/or 
pfhrp3 (pfhrp2/3) genes [19, 20].
The methods required to identify and confirm pfhrp2/3 
gene deletions are challenging, due to the difficulty of 
proving the absence of a gene. While PCR assays that tar-
get pfhrp2/3 are expected to yield negative results when 
applied to parasites lacking the gene(s), PCR failure can 
occur for other reasons. Testing of parasites with intact 
pfhrp2/3 genes may yield false-negative results due to 
DNA concentrations below the assay’s limit of detection, 
Open Access
Malaria Journal
*Correspondence:  jonathan_parr@med.unc.edu 
†Jonathan B. Parr and Olivia Anderson are co-first authors 
1 Division of Infectious Diseases, Department of Medicine, University 
of North Carolina, 130 Mason Farm Rd, Chapel Hill, NC 27599, USA
Full list of author information is available at the end of the article
Page 2 of 8Parr et al. Malar J  (2018) 17:137 
poor quality DNA, variable reagent performance, or 
other factors.
Cheng et  al. published useful guidelines to standard-
ize the reporting of pfhrp2/3 gene deletions [21]. How-
ever, the specific methods employed for the detection 
and confirmation of deletions continue to vary between 
laboratories, and recent evidence suggests that atypical 
elongation temperatures may improve amplification of 
AT-rich regions of both genes [14, 22]. This manuscript 
seeks to address these issues by comparing the perfor-
mance of published PCR assays for pfhrp2 and pfhrp3, 
exploring the impact of reduced elongation tempera-
tures on assay sensitivity, assessing assay specificity, and 
describing a streamlined testing algorithm.
Methods
The performance characteristics of six published PCR 
assays, including four designed to amplify pfhrp2 and two 
designed for pfhrp3, were compared [3, 5, 9, 23]. After 
determining the optimal annealing temperatures for each 
assay, we assessed their lower limits of detection (LOD) 
using DNA extracted from cultured P. falciparum 3D7 
strain parasites. DNA was quantified using the Qubit 2.0 
instrument with dsDNA high sensitivity reagents (Ther-
moFisher Scientific, Waltham, MA) and serially diluted 
in nuclease-free water to achieve concentrations rang-
ing from  10−1 to  10−7  ng/µL (seven tenfold dilutions). 
For each dilution, the assay was performed in triplicate, 
using different elongation temperatures of 60, 65, and 
72 °C. PCR assays were performed on Mastercycler ther-
mocyclers (model AG 22331; Eppendorf, Hamburg, Ger-
many) using 25 µL reaction volumes containing 12.5 µL 
HotStarTaq Master Mix (Qiagen, Venlo Netherlands), 
200–400 nM primers synthesized by Eurofins Genomics 
(Louisville, KY) with salt-free purification, nuclease-free 
water, and 3  µL of DNA template (Table  1). For nested 
reactions, first-round product was diluted 100-fold in 
nuclease-free water prior to second-round amplifica-
tion. PCR products were visualized using electrophoresis 
with 1% agarose gels in TBE buffer (Tris/Borate/EDTA). 
Finally, LOD testing was repeated using optimized reac-
tion conditions and serial dilutions of 3D7 DNA from a 
separate stock.
The specificity of the best performing assays, includ-
ing those with targets spanning exon 1 and 2 (exon 1/2) 
and exon 2 alone, was then evaluated. Assays were per-
formed using control DNA from P. falciparum Dd2 
(MRA-150G) and HB3 (MRA-155G) strain parasites, 
which lack pfhrp2 and pfhrp3, respectively. Control DNA 
was obtained from the Malaria Research and Reference 
Reagent Resource Center ([MR4], BEI Resources, Manas-
sas, Virginia) and diluted to a concentration of 0.1  ng/
µL after initial quantification using Qubit as above. For 
assays that yielded an unexpected result using optimized 
reaction conditions (i.e. bands from a pfhrp2 assay per-
formed using pfhrp2-deleted Dd2 DNA or bands from 
a pfhrp3 assays performed using pfhrp3-deleted HB3 
DNA), amplicons were sequenced using Sanger sequenc-
ing at Eton Bioscience (Research Triangle Park, NC), and 
assays were repeated at the other elongation tempera-
tures (60, 65, and/or 72 °C). For PCR products with mul-
tiple bands appreciated by gel electrophoresis, individual 
bands were excised, and DNA was extracted using the 
QIAquick Gel Extraction Kit (Qiagen, Hilden, Germany) 
before sequencing. Gel extraction was performed accord-
ing to the manufacturer’s instructions, with the exception 
of the final DNA elution step, in which we performed 
two separate elutions using 30  µL aliquots of Buffer EB 
through the column, followed by a final elution step using 
the combined 60 µL initial eluate to maximize DNA yield. 
Raw sequence reads were processed using Sequencher 
5.4 (Gene Codes Corporation, Ann Arbor, MI), trim-
ming bidirectional sequences based on confidence values 
and visual inspection of the chromatograms. We used 
EMBOSS Water for pairwise nucleotide alignments to 
the 3D7 (v3.0) pfhrp2 and pfhrp3 reference sequences. 
Sequence identification was based on sequence homol-
ogy and alignment score, using default settings (DNAfull 
matrix, gap open penalty 10, gap extend penalty 0.5) [24].
Results
Assay performance
Reduced elongation temperatures improved the sensitiv-
ity of five of the six assays (Additional file 1: Figures S1, 
S2). An elongation temperature of 60  °C reduced the 
LOD by tenfold and/or produced darker bands for all 
exon 1/2 targets and for the first-round reaction of a sin-
gle exon 2 target (assay 4). Using optimized elongation 
temperatures and under our lab conditions, the LOD 
of published PCR assays for pfhrp2 and pfhrp3 varied, 
with lower limits ranging from approximately 0.01  pg/
µL to 0.1 ng/µL of 3D7 DNA, or approximately 0.4–4000 
parasite genomes/µL (Table  1). Additionally, while add-
ing a second round of amplification in the best perform-
ing nested PCR for pfhrp2 exon 1/2 (assay 1) resulted in 
darker bands, the assay’s LOD was unchanged.
Amplification of paralogous genes by exon 1/2 assays
Unexpectedly, paralogous amplification by assays target-
ing exon 1/2 but not exon 2 of both genes was observed. 
Bands were visualized from assays targeting exon 1/2 of 
pfhrp2 (assay 1) using Dd2 (pfhrp2-deleted) control DNA 
(Additional file 1: Figure S3) and those targeting exon 1/2 
of pfhrp3 (assay 5) using HB3 (pfhrp3-deleted) control 
DNA (Additional file  1: Figure S4), respectively. Assay 
1 produced unexpected bands at all three extension 
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Table 1 Published pfhrp2/3 primer sequences, limits of detection, and optimized conditions
LOD lower limit of detection; MM master mix; Vol volume; Bp base pair
* Typical LOD under the conditions of this laboratory. Assay performance varied between runs, but consistently achieved LODs within one  log10 of the listed LOD
Assay # Target Primer sequences (5′→3′) Reaction conditions Cycling parameters LOD,* ng/µL 
(genomes/µL)
Ref
1 pfhrp2 (exon 1/2) Outer:
 For: GGT TTC CTT CTC AAA AAA 
TAAAG 
 Rev: TCT ACA TGT GCT TGA 
GTT TCG 
Optional—inner:
 For: GTA TTA TCC GCT GCC GTT 
TTT GCC 
 Rev: CTA CAC AAG TTA TTA TTA 
AAT GCG GAA 
200 nM each primer
HotStarTaq MM (Qiagen, 
Venlo, Netherlands)
3 μL template DNA or 
100 × diluted first-round 
product
25 μL reaction vol
95 °C × 15 min; 40 cycles of 
94 °C × 1 min, 50 °C × 1 min 
for outer primers or 
55 °C × 1 min for inner 
primers, 60 °C × 1 min; 
60 °C × 10 min
10−5 (~ 0.4) [3]
2 pfhrp2 (exons 1/2) For: TAT CCG CTG CCG TTT 
TTG CC
Rev: AGC ATG ATG GGC ATC 
ATC CTA 
400 nM each primer HotStar-
Taq MM
3 μL template DNA
25 μL reaction vol
95 °C × 15 min; 40 cycles 
of 94 ° × 1 min, 57 °C 
x 1 min, 60 °C × 1 min; 
60 °C × 10 min
10−1 (~ 4000) [9]
3 pfhrp2 (exon 2) For: ATT CCG CAT TTA ATA ATA 
ACT TGT GTAGC 
Rev: ATG GCG TAG GCA ATG 
TGT GG
400 nM each primer
HotStarTaq MM
3 μL template DNA
25 μL reaction vol
95 °C × 15 min;
40 cycles of 94 °C × 1 min, 
59 °C × 1 min, 
72 °C × 1 min;
72 °C × 10 min
10−4 (~ 4) [5]
4 pfhrp2 (exon 2) Outer:
 For: CAA AAG GAC TTA ATT TAA 
ATA AGA G
 Rev: AAT AAA TTT AAT GGC GTA 
GGCA 
Optional—inner (hemi-
nested):
 For: ATT ATT ACA CGA AAC TCA 
AGCAC 
 Rev: AAT AAA TTT AAT GGC GTA 
GGCA 
400 nM each primer
HotStarTaq MM
3 μL template DNA or 100× 
diluted first-round product
25 μL reaction vol
95 °C × 15 min;
40 cycles of 94 °C × 1 min, 
57 °C × 1 min for outer 
primers or 62 °C for inner 
primers, 60 °C × 1 min;
60 °C × 10 min
10−4 (~ 4) [23]
5 pfhrp3 (exons 1/2) For: TAT CCG CTG CCG TTT TTG 
CTTCC 
Rev: TGC ATG ATG GGC ATC 
ACC TG
400 nM primers
HotStarTaq MM
3 μL template DNA
25 μL reaction vol
95 °C × 15 min;
40 cycles of 94 °C × 1 min, 
60 °C × 1 min, 
60 °C × 1 min;
60 °C × 10 min
10−4 (~ 4) [9]
6 pfhrp3 (exon 2) Outer:
For: AAT GCA AAA GGA CTT 
AAT TC
Rev: TGG TGT AAG TGA TGC 
GTA GT
Optional—inner (hemi-
nested):
 For: AAA TAA GAG ATT ATT ACA 
CGA AAG 
 Rev: TGG TGT AAG TGA TGC 
GTA GT
400 nM primers
HotStarTaq MM
3 μL template DNA or 
100 × diluted first-round 
product
25 μL reaction vol
95 °C × 15 min;
40 cycles of 94 °C × 1 min, 
55 °C × 1 min, 
60 °C × 1 min;
60 °C × 10 min
10−4 (~ 4) [23]
7 pfldh (initial qPCR) For: ACG ATT TGG CTG GAG 
CAG AT
Rev: TCT CTA TTC CAT TCT TTG 
TCA CTC TTTC 
Probe: FAM-GTA ATA GTA ACA 
GCT GGA TTT ACC AAG GCC 
CCA-TAMRA
200 nM primers
100 nM probe
Probe Master qPCR Mix 
(Roche Diagnostics, Indian-
apolis, IN)
2 μL template DNA
12 μL reaction vol
50 °C × 2 min;
95 °C × 10 min;
40 cycles of 95 °C × 15 s, 
60 °C × 1 min
10−4 (~ 4) [31]
8 Pf -tubulin (confirmatory) For: AAT AAA TCA TAA TGA TGT 
GCG CAA GTG ATC C
Rev: AAT AAA TCA TAA TCC TTT 
GTG GAC ATT CTT CCTC 
300 nM primers
FastStart Universal SYBR Green 
MM (Roche Diagnostics)
3 µL template DNA
25 µL reaction volume
50 °C × 2 min;
95 °C × 10 min;
40 cycles of 95 °C × 15 s, 
60 °C × 1 min;
Dissociation analysis
10−3 (~ 40) [32, 33]
Page 4 of 8Parr et al. Malar J  (2018) 17:137 
temperatures tested, while assay 5 produced bands when 
tested using 60 and 65 °C extension temperatures but not 
at 72  °C. All tested exon 2 assays for both genes (assay 
3, 4, and 6) produced negative results using Dd2 or HB3 
DNA, as expected. Pfhrp2 exon 1/2 assay 2 was not tested 
due to its poor performance during initial LOD testing, 
presumably a result of a single base insertion near the 
3′ end of the reverse primer compared to the 3D7 refer-
ence sequence. The sequence homology of pfhrp2 and 
pfhrp3 exon 1/2 primer binding sites (Fig.  1) suggested 
that amplification of paralogous genes had occurred—
i.e., the amplicons generated by the pfhrp2 exon 1/2 assay 
using Dd2 strain control DNA represented pfhrp3 ampli-
fication and that those generated by the pfhrp3 exon 1/2 
assay using HB3 strain control DNA represented pfhrp2 
amplification.
Sequencing results confirmed amplification of pfhrp3 
by the pfhrp2 exon 1/2 assay, and vice versa. With Dd2 
strain (pfhrp2-deleted) template, the pfhrp2 exon 1/2 
assay (assay 1) unexpectedly produced a single band 
with a fragment length of approximately 300  bp. The 
amplicon’s sequence aligned to the pfhrp3 gene with 
92% sequence homology (Additional file  1: Figure S5). 
With HB3 strain (pfhrp3-deleted) template, the pfhrp3 
exon 1/2 assay (assay 5) unexpectedly produced two 
clear bands with fragment lengths of approximately 300 
and 800  bp and a faint band at approximately 400  bp. 
Sequences generated using DNA extracted from each 
band aligned to the pfhrp2 gene, with 98, 99, and 97% 
sequence homology for the 300, 400, and 800  bp frag-
ments, respectively (Additional file  1: Figure S6). How-
ever, when applied to 3D7 strain (pfhrp2/3-positive) 
control template, both exon 1/2 assays produced the 
expected result: a single band with a sequence that 
aligned to pfhrp2 with 96% homology or pfhrp3 with 99% 
sequence homology (for assays 1 and 5, respectively).
Fig. 1 Pfhrp2 and pfhrp3 gene sequence homology. Alignment of reference sequences from the consensus 3D7 (v3.0) genome, 5′→3′, with 
expected binding sites for pfhrp2 assays (white boxes) and pfhrp3 assays (gray boxes). The reverse primer sequence for Assay 2 includes an a 
single-base insertion (cytosine) at the location indicated by an asterisk (*). Identical bases are indicated by a period (.), missing bases by a dash (-), 
substitutions by the discordant base, and non-coding regions by lower case font
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Streamlined testing algorithm
These findings were used to develop a streamlined, PCR-
based testing pipeline for pfhrp2/3-negative P. falciparum 
(Fig. 2) that incorporates optimized elongation tempera-
tures, LOD testing results, and assay specificity.
Discussion
By lowering the LOD and employing assays that distin-
guish pfhrp2 from pfhrp3, this testing algorithm pro-
vides an improved approach to PCR-based detection of 
pfhrp2/3-negative P. falciparum. Importantly, PCR-based 
approaches for identification of pfhrp2- and pfhrp3-
negative parasites must be coupled with verification of P. 
falciparum parasitaemia and confirmation that parasite 
DNA is present at concentrations above the LODs of the 
pfhrp2 and pfhrp3 assays. These goals were achieved by 
employing assays targeting two P. falciparum-specific, 
single-copy genes, lactate dehydrogenase (pfldh) and P. 
falciparum beta tubulin (PfBtubulin), as the initial and 
final steps of the testing pipeline.
Lowering the elongation temperature improved the 
LOD of all published assays with exon 1/2 targets on 
either gene. This finding likely represents improved 
amplicon extension across the AT-rich intron between 
the exons as suggested by previous reports [22]. Unex-
pected amplification of paralogous gene targets by 
the pfhrp2 and pfhrp3 exon 1/2 assays was observed, 
presumably due to sequence homology at the primer 
binding sites. In regions where co-existing pfhrp2 and 
pfhrp3 deletions are common, the impact of non-spe-
cific amplification is expected to be reduced [25–27]. 
Additionally, the absence of paralogous amplification 
of 3D7 control DNA suggests that the availability of 
abundant, completely homologous primer binding 
sites early in PCR cycling reduces the likelihood of 
exponential amplification after mispriming. To reduce 
the risk of unintentional amplification of paralogous 
Fig. 2 Proposed testing pipeline. Single-step assays are favoured to reduce the risk of contamination, and assays should be performed in duplicate. 
In addition to positive P. falciparum (e.g. 3D7 strain) DNA and no template controls, either *pfhrp2-negative (e.g. Dd2 strain) or **pfhrp3-negative (e.g. 
HB3 strain) P. falciparum DNA controls should be used
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genes, this testing algorithm uses assays targeting exon 
2 of both genes. This approach also permits analysis of 
the repetitive sequences that encode epitopes recog-
nized by anti-PfHRP2 antibodies [28].
A broad range of LOD results was observed for 
published pfhrp2 and pfhrp3 assays, spanning over 4 
orders of magnitude under the laboratory conditions 
employed during this study. These differences were 
addressed in the resulting testing pipeline (Fig.  2) by 
defining an initial threshold DNA concentration ten-
fold higher than the LOD of the downstream pfhrp2 
and pfhrp3 assays. In addition, a stringent, final single-
copy-gene PCR that meets the same LOD requirement 
was included, providing confirmation that sample 
degradation has not occurred during the testing pro-
cess. The typical workflow employed in this laboratory 
includes assays 3 and 6 for pfhrp2 and pfhrp3 testing, 
respectively, performed in duplicate. For discordant 
results (i.e. one of two replicates positive), samples 
are called positive if there is a clear band of appropri-
ate fragment length. If not, the assay is repeated, and 
the final call is based on the third result. Because the 
first-round of the nested assays achieved LODs below 
the initial and final confirmatory, falciparum-specific 
assays, their use as single-step assays is favoured in 
this laboratory to reduce the risk of contamination and 
improve work flow.
In settings where real-time PCR is not feasible, the 
proposed initial lactate dehydrogenase (pfldh) quanti-
tative PCR assay and the final confirmatory P. falcipa-
rum beta tubulin (PfBtubulin) assays could be replaced 
with traditional PCR assays with LODs above the LOD 
of the pfhrp2 and pfhrp3 assays. Because assay per-
formance can vary from laboratory to laboratory and 
with different reagents or equipment, it is essential to 
confirm the LOD of each assay using the reagents and 
laboratory infrastructure at hand.
In addition to PCR-based testing, current guidelines 
recommend independent confirmation of P. falcipa-
rum parasitaemia using microscopy or a non-PfHRP2-
based RDT, such as an RDT that detects P. falciparum 
lactate dehydrogenase (pf-pLDH), before making dele-
tion calls [19, 21]. Quantification of circulating 
PfHRP2 antigen is also a valuable tool that can be par-
ticularly useful for assessing PfHRP2-RDT-negative 
but pfhrp2/3-PCR-positive isolates with impaired pro-
tein expression [29]. Additionally, novel assays under 
development such as those targeting regionally spe-
cific deletion breakpoints or employing droplet digital 
PCR, have potential to improve throughput [30].
Conclusions
Surveillance of pfhrp2- and pfhrp3-negative P. falciparum 
requires careful laboratory workflows. PCR-based testing 
methods, coupled with microscopy and/or antigen test-
ing, serve as useful tools to support policy development. 
Standardized approaches to the detection of pfhrp2- and 
pfhrp3-negative P. falciparum should inform efforts to 
define the impact of these parasites [20, 21].
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Additional files
Additional file 1: Figure S1. Pfhrp2 assay performance using serially 
diluted P. falciparum 3D7 strain DNA. Elongation temperatures were varied 
as listed below. All other reaction conditions are specified in Table 1. 
Figure S2. Pfhrp3 assay performance using serially diluted P. falciparum 
3D7 strain DNA. Elongation temperatures were varied as listed below. All 
other reaction conditions are specified in Table 1. Figure S3. Representa-
tive agarose gel electrophoresis depicting unexpected spurious bands 
from Dd2 strain (pfhrp2-deleted) control DNA. PCR targeting pfhrp2 
exon 1/2 (assay 1 outer) yielded a spurious ~ 300 bp band from serial 
dilutions of pfhrp2-deleted Dd2 strain control DNA at all three elongation 
temperatures. Figure S4. Representative agarose gel electrophoresis 
depicting unexpected spurious bands from HB3 strain (pfhrp3-deleted) 
control DNA. PCR targeting pfhrp3 exon 1/2 (assay 5) yielded spurious 
bands at ~ 300, 400, and 800 bp from serial dilutions of Dd2 strain control 
DNA using optimized elongation temperatures (Table 1). Figure S5. 
Pfhrp3 assay performance using serially diluted P. falciparum 3D7 strain 
DNA. Elongation temperatures were varied as listed below. All other reac-
tion conditions are specified in Table 1. The sequence of pfhrp2 exon 1/2 
(assay 1) PCR product aligns to pfhrp3, due to spurious PCR amplification 
of the Dd2 pfhrp3 gene. PCR was performed using 0.01 ng/μL of 3D7 
(pfhrp2-positive) and Dd2 (pfhrp2-negative) control DNA, respectively (see 
Additional file 1: Figure S3), followed by Sanger sequencing of amplicons. 
Reference sequences from the consensus 3D7 (v3.0) genome for pfhrp2 
and pfhrp3 are displayed on the top two rows (REF), from 5′→ 3′, with 
capital letters for coding regions and genetic coordinates in reference 
to the pfhrp2 gene. Identical bases are indicated by a period (.), missing 
bases by a dash (-), substitutions by the discordant base. PCR product 
sequence contigs are highlighted as follows: 3D7 control DNA (light gray); 
Dd2 control DNA (dark gray). Figure S6. The sequences of pfhrp3 exon 
1/2 (assay 5) PCR product align to pfhrp2, due to spurious PCR amplifica-
tion of the HB3 pfhrp2 gene. PCR was performed using 0.01 ng/μL of 3D7 
(pfhrp3-positive) and HB3 (pfhrp3-negative) control DNA, respectively (see 
Additional file 1: Figure S4), followed by Sanger sequencing of amplicons. 
Reference sequences from the consensus 3D7 (v3.0) genome for pfhrp2 
and pfhrp3 are displayed on the top two rows (REF), from 5′→ 3′, with 
capital letters for coding regions and genetic coordinates in reference to 
the pfhrp3 gene. Identical bases are indicated by a period (.), missing bases 
by a dash (-), substitutions by the discordant base. PCR product sequence 
contigs are highlighted as follows: 3D7 control DNA (medium gray) and 
HB3 control DNA 300 bp fragment (light gray), 400 bp fragment (medium 
gray), and 800 bp fragment (dark gray)
Additional file 2. FASTA file containing Sanger sequences of amplicons 
produced by pfhrp2/3 exon 1/2 assays when applied to Dd2 (pfhrp2-nega-
tive), HB3 (pfhrp3-negative), and 3D7 (pfhrp2/3-positive) DNA
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